Search

FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.

Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US

Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.

Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function

FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

Employees join #stayhomeandfoster movement

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)

New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF

FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US

FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US

IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US